CoChat

STAT3 controls COL1A2 enhancer activation cooperatively with JunB, regulates type I collagen synthesis posttranscriptionally, and is essential for lung myofibroblast differentiation

Open access
Papaioannou, Ioannis, Xu, Shiwen, Denton, Christopher P., Abraham, David J., Ponticos, Markella · 2018 · Molecular Biology of the Cell

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Fibroblast differentiation is a key cellular process that underlies the process of fibrosis, a deadly complication of fibrotic diseases like scleroderma (SSc). This transition coincides with the overproduction of collagen type I (COL1) and other extracellular matrix proteins. High-level expression of the collagen type 1α2 subunit (COL1A2), requires the engagement of a far-upstream enhancer, whose activation is strongly dependent on the AP1 factor JunB. We now report that STAT3 also binds the COL1A2 enhancer and is essential for RNA polymerase recruitment, without affecting JunB binding. STAT3 is required for the increased COL1A2 expression observed in myofibroblasts. We also report that TGFβ partially activates STAT3 and show that inhibiting STAT3 potently blocks TGFβ signaling, matrix remodeling, and TGFβ-induced myofibroblast differentiation. Activation of STAT3 with IL6 transsignaling alone, however, only increased COL1A2 protein expression, leaving COL1A2 mRNA levels unchanged. Our results suggest that activated STAT3 is not the limiting factor for collagen enhancer activation in human lung fibroblasts. Yet, a certain threshold level of STAT3 activity is essential to support activation of the COL1A2 enhancer and TGFβ signaling in fibroblasts. We propose that STAT3 operates at the posttranscriptional as well as the transcriptional level.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1091/mbc.e17-06-0342

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1: (A) The structure of the COL1A2 far-upstream enhancer (FUE) showing the proximal promoter (PP), three of the five DNAse hypersensitive sites (HS3–5), the critical AP-1 element in HS4, and the two putative STAT3 sites (arrows indicate DNA strand). (B) Reporter gene analysis of enhancer activation in normal (n = 3) and SSc (n = 3) lung fibroblasts treated with the JAK/STAT inhibitor AG490. The structure of the two DNA constructs used is shown at the top. The WT construct contains all elements of the FUE and PP fused to the firefly luciferase gene, while in ΔHS4 the HS4 region has been deleted to inactivate the enhancer. The results are normalized using a Renilla luciferase transfection control. (C) DNA gel showing the results of a ChIP assay for phosphoSTAT3 near the HS4 region in SSc lung fibroblasts treated with IL6 plus the soluble receptor α(IL6xRα) and SD1029. (D) Western blot of nuclear extracts from the same cells used in C, showing nuclear phosphoSTAT3 levels. TATA binding protein (TBP) was used as the house keeping gene. (E) ChIP analysis using qPCR for the binding of STAT3, JunB, and RNA polymerase II, in the HS4 region of SSc fibroblasts after treatment with SD1029, STAT3 siRNA (siSTAT3), or nontargeting siRNA (siNT). * = p < 0.05.
FIGURE 1: (A) The structure of the COL1A2 far-upstream enhancer (FUE) showing the proximal promoter (PP), three of the five DNAse hypersensitive sites (HS3–5), the critical AP-1 element in HS4, and the two putative STAT3 sites (arrows indicate DNA strand). (B) Reporter gene analysis of enhancer activation in normal (n = 3) and SSc (n = 3) lung fibroblasts treated with the JAK/STAT inhibitor AG490. The structure of the two DNA constructs used is shown at the top. The WT construct contains all elements of the FUE and PP fused to the firefly luciferase gene, while in ΔHS4 the HS4 region has been deleted to inactivate the enhancer. The results are normalized using a Renilla luciferase transfection control. (C) DNA gel showing the results of a ChIP assay for phosphoSTAT3 near the HS4 region in SSc lung fibroblasts treated with IL6 plus the soluble receptor α(IL6xRα) and SD1029. (D) Western blot of nuclear extracts from the same cells used in C, showing nuclear phosphoSTAT3 levels. TATA binding protein (TBP) was used as the house keeping gene. (E) ChIP analysis using qPCR for the binding of STAT3, JunB, and RNA polymerase II, in the HS4 region of SSc fibroblasts after treatment with SD1029, STAT3 siRNA (siSTAT3), or nontargeting siRNA (siNT). * = p < 0.05.CC BY-NC-SA · PubMed Central
FIGURE 2: (A) Normal and scleroderma fibroblasts (n = 3, * = p < 0.05 by Student’s t test) treated with IL6xRα and SD1029. (B) The effect of SD1029 on STAT3 Y705 phosphorylation, FN1 protein, and COL1 protein in serum-starved scleroderma lung fibroblasts. (C) The effect of STAT3 down-regulation with siRNA on COL1A2 and EDA–fibronectin mRNA expression in scleroderma lung fibroblasts (n = 3, * = p < 0.05). (D) Serum-starved scleroderma lung fibroblasts were treated with IL6xRα, TGFβ, and SD1029 for 24 h before assaying COL1A2 mRNA levels (n = 3, * = p < 0.05).
FIGURE 2: (A) Normal and scleroderma fibroblasts (n = 3, * = p < 0.05 by Student’s t test) treated with IL6xRα and SD1029. (B) The effect of SD1029 on STAT3 Y705 phosphorylation, FN1 protein, and COL1 protein in serum-starved scleroderma lung fibroblasts. (C) The effect of STAT3 down-regulation with siRNA on COL1A2 and EDA–fibronectin mRNA expression in scleroderma lung fibroblasts (n = 3, * = p < 0.05). (D) Serum-starved scleroderma lung fibroblasts were treated with IL6xRα, TGFβ, and SD1029 for 24 h before assaying COL1A2 mRNA levels (n = 3, * = p < 0.05).CC BY-NC-SA · PubMed Central
FIGURE 3: (A) Serum-starved lung scleroderma fibroblasts (n = 2) were treated with IL6xRα for 0.5, 2, or 16 h or left untreated. Protein was analyzed by Western blotting and densitometry. A representative blot matching the average is shown. The first histograph shows the normalized density of the bands in the Western shown here. The other histogram on the right shows the average normalized collagen levels from three independent experiments, each with a different fibroblast line (n = 3, * = p < 0.05). (B) Transcriptional analysis of COL1A1, COL1A2, and EDA–FN1 from the cell lines (n = 2) treated as in A. (C) Analysis of COL1 in the media of scleroderma (SSc) and healthy control lung fibroblasts treated with IL6xRα with or without 7.5 µM SD1029 for 16 h. (D) Transcriptional analysis of SOCS3 in response to IL6xRα. * = p < 0.05.
FIGURE 3: (A) Serum-starved lung scleroderma fibroblasts (n = 2) were treated with IL6xRα for 0.5, 2, or 16 h or left untreated. Protein was analyzed by Western blotting and densitometry. A representative blot matching the average is shown. The first histograph shows the normalized density of the bands in the Western shown here. The other histogram on the right shows the average normalized collagen levels from three independent experiments, each with a different fibroblast line (n = 3, * = p < 0.05). (B) Transcriptional analysis of COL1A1, COL1A2, and EDA–FN1 from the cell lines (n = 2) treated as in A. (C) Analysis of COL1 in the media of scleroderma (SSc) and healthy control lung fibroblasts treated with IL6xRα with or without 7.5 µM SD1029 for 16 h. (D) Transcriptional analysis of SOCS3 in response to IL6xRα. * = p < 0.05.CC BY-NC-SA · PubMed Central
FIGURE 4: (A) Schematic illustrating the treatment regime. Serum-starved SSc fibroblasts were treated with two doses of IL6xRα 4 h apart. TGFβ, where appropriate, was added together with the first IL6xRα. SD1029 was only added just before the first IL6xRα treatment at zero hours. (B) Protein level analysis of treated cells by Western blotting and densitometry. Transcriptional analysis of (C) COL1A1, COL1a2, and EDA–FN1 and (D) SERPINE1 (PAI-1).
FIGURE 4: (A) Schematic illustrating the treatment regime. Serum-starved SSc fibroblasts were treated with two doses of IL6xRα 4 h apart. TGFβ, where appropriate, was added together with the first IL6xRα. SD1029 was only added just before the first IL6xRα treatment at zero hours. (B) Protein level analysis of treated cells by Western blotting and densitometry. Transcriptional analysis of (C) COL1A1, COL1a2, and EDA–FN1 and (D) SERPINE1 (PAI-1).CC BY-NC-SA · PubMed Central
FIGURE 5: (A) Three normal and three scleroderma lung fibroblasts were serum starved overnight and Western blotting used to determine STAT3 phosphorylation. The ratio of pSTAT3 to STAT3 was determined by densitometry (arbitrary units). (B) Levels of STAT3 phosphorylation from A averaged for scleroderma and normal fibroblasts. Statistical analysis was done with the Student’s t test. (C) Immunohistochemistry for STAT3 in lung sections from normal volunteers and scleroderma patients.
FIGURE 5: (A) Three normal and three scleroderma lung fibroblasts were serum starved overnight and Western blotting used to determine STAT3 phosphorylation. The ratio of pSTAT3 to STAT3 was determined by densitometry (arbitrary units). (B) Levels of STAT3 phosphorylation from A averaged for scleroderma and normal fibroblasts. Statistical analysis was done with the Student’s t test. (C) Immunohistochemistry for STAT3 in lung sections from normal volunteers and scleroderma patients.CC BY-NC-SA · PubMed Central
FIGURE 6: (A) Immunofluorescence for type I procollagen (green) and EDA–fibronectin (red) in normal and scleroderma serum-starved lung fibroblasts treated with SD1029. (B) Immunofluorescence for αSMA (green) in normal and scleroderma lung fibroblasts treated with TGFβ and SD1029. The actin cytoskeleton was stained red with phalloidin. (C) Collagen gel contraction assay (n = 3, * = p < 0.05 with a Student’s t test) in scleroderma cells treated with TGFβ, SD1029, and siRNA against STAT3 or nontargeting (NT) siRNA. Normal fibroblasts failed to contract the gel sufficiently to achieve statistical significance.
FIGURE 6: (A) Immunofluorescence for type I procollagen (green) and EDA–fibronectin (red) in normal and scleroderma serum-starved lung fibroblasts treated with SD1029. (B) Immunofluorescence for αSMA (green) in normal and scleroderma lung fibroblasts treated with TGFβ and SD1029. The actin cytoskeleton was stained red with phalloidin. (C) Collagen gel contraction assay (n = 3, * = p < 0.05 with a Student’s t test) in scleroderma cells treated with TGFβ, SD1029, and siRNA against STAT3 or nontargeting (NT) siRNA. Normal fibroblasts failed to contract the gel sufficiently to achieve statistical significance.CC BY-NC-SA · PubMed Central
FIGURE 7: Scratch wound assay with a scleroderma lung fibroblast line and SD1029. The cells were plated in 24-well plates, allowed to reach confluence, and serum starved overnight with 0.1% BSA in DMEM. A scratch was made with a pipette tip and mitomycin C was added to prevent proliferation. The cells were allowed to migrate overnight with or without 10 µM SD1029. The experiment was carried out in triplicate. The area of the gap was measured with ImageJ and the percentage of closure was calculated as (area at 24 h)/(area at 0 h) × 100. The differences between untreated and treated SD1029 were not statistically significant with a Student’s t test.
FIGURE 7: Scratch wound assay with a scleroderma lung fibroblast line and SD1029. The cells were plated in 24-well plates, allowed to reach confluence, and serum starved overnight with 0.1% BSA in DMEM. A scratch was made with a pipette tip and mitomycin C was added to prevent proliferation. The cells were allowed to migrate overnight with or without 10 µM SD1029. The experiment was carried out in triplicate. The area of the gap was measured with ImageJ and the percentage of closure was calculated as (area at 24 h)/(area at 0 h) × 100. The differences between untreated and treated SD1029 were not statistically significant with a Student’s t test.CC BY-NC-SA · PubMed Central
FIGURE 8: The effect of IL6 on the eIF2α and eIF4e pathways. Primary lung fibroblast cultures from SSc patients were serum starved overnight. The media was replaced with fresh serum-free media containing IL6xRα or the equivalent volume of PBS and protein was harvested after 30 min, 2 h, or 16 h. STAT3 phosphorylation is shown as a positive control for IL6. eIF2α phosphorylation was investigated as a measure of eIF2α deactivation and 4EBP1 expression/phosphorylation was investigated as a measure for eIF4e activation.
FIGURE 8: The effect of IL6 on the eIF2α and eIF4e pathways. Primary lung fibroblast cultures from SSc patients were serum starved overnight. The media was replaced with fresh serum-free media containing IL6xRα or the equivalent volume of PBS and protein was harvested after 30 min, 2 h, or 16 h. STAT3 phosphorylation is shown as a positive control for IL6. eIF2α phosphorylation was investigated as a measure of eIF2α deactivation and 4EBP1 expression/phosphorylation was investigated as a measure for eIF4e activation.CC BY-NC-SA · PubMed Central
FIGURE 9: (A) Interaction between the COL1A2 enhancer and promoter in the presence of STAT3. (B) The enhancer without STAT3. STAT3 acts as a bridge helping to engage the promoter and enhancer, while JunB recruits RNA polymerase. (C) The role of STAT3 in early TGFβ signaling. Basal STAT3 signaling and STAT3 directly induced by TGFβ is sufficient to interact with AP1/JunB and together with SMADs induce early transcriptional activation of matrix proteins. High STAT3 activation enhances translation. The increased expression of profibrotic matrix proteins triggers matrix remodeling, reinforces the TGFβ autocrine loop, and initiates myofibroblast differentiation.
FIGURE 9: (A) Interaction between the COL1A2 enhancer and promoter in the presence of STAT3. (B) The enhancer without STAT3. STAT3 acts as a bridge helping to engage the promoter and enhancer, while JunB recruits RNA polymerase. (C) The role of STAT3 in early TGFβ signaling. Basal STAT3 signaling and STAT3 directly induced by TGFβ is sufficient to interact with AP1/JunB and together with SMADs induce early transcriptional activation of matrix proteins. High STAT3 activation enhances translation. The increased expression of profibrotic matrix proteins triggers matrix remodeling, reinforces the TGFβ autocrine loop, and initiates myofibroblast differentiation.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

Metadata

Authors
Papaioannou, I., Xu, S., Denton, C. P., Abraham, D. J., & Ponticos, M.
Affiliations
University College London (GB)
Corresponding author
Ponticos, Markella
Venue
Molecular Biology of the Cell
Published
2018-01-15
Volume
29
Issue
2
Pages
84-95
ISSN
  • 1059-1524 (ISSN-L)
  • 1939-4586
OpenAlex
W2769262718
Cited by
64
References
33
Citations by year
2026: 6 · 2025: 4 · 2024: 5 · 2023: 6 · 2022: 10 · 2021: 14 · 2020: 6 · 2019: 8 · 2018: 5
FWCI
2.29
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Molecular Biology of the Cell (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Rosetrees Trust (M96-F1)
  • Versus Arthritis (19427, 18420)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
STAT3, COL1A2, type I collagen, enhancer activation, JunB, AP-1, myofibroblast differentiation, lung fibroblasts, TGF-beta signaling, post-transcriptional regulation, RNA polymerase recruitment, extracellular matrix remodeling, systemic sclerosis, fibrosis
MeSH terms
Cell Differentiation, Cells, Cultured, Enhancer Elements, Genetic, Fibrosis, Gene Expression Regulation, Humans, Lung, Transcription Factors, Signal Transduction, Interleukin-6, Transforming Growth Factor beta, Collagen Type I, STAT3 Transcription Factor, Myofibroblasts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.